Stryker Corporation research snapshot
SYK AI stock analysis currently reads Stryker Corporation as a high-quality medical technology franchise with durable Orthopaedics, MedSurg, and Neurotechnology demand, a strong Mako robotics position, and a long record of acquisitive growth. At the July 8, 2026 data cutoff, SYK closed at $329.74 with market capitalization near $126.41 billion. The business score is strong, but the SYK AI stock forecast uses scenario ranges because the current price still embeds high execution expectations after Q1 2026 cyber-related shipment delays. This page is informational research and not investment advice.
Current price
$329.74 close on July 7, 2026
Market cap
$126.41 billion
AI score
73 / 100
Rating
High-quality MedTech compounder with strong procedure demand, premium valuation, integration work, and temporary cyber disruption risk
Trend status
Recovering above common moving averages, but still well below the 52-week high after a difficult first half
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Stryker sells implants, surgical equipment, neurovascular products, emergency care tools, endoscopy systems, and robotic-assisted orthopedic platforms to hospitals and healthcare providers. | High |
| Moat | Moat comes from surgeon training, clinical workflow familiarity, hospital relationships, implant ecosystems, Mako robotics, scale, regulatory know-how, and broad procedure coverage. | High |
| Management | CEO Kevin A. Lobo has led a long acquisition and innovation cycle, but current execution is judged by margin recovery, integration discipline, cyber resilience, and organic sales recovery. | Medium-high |
| Financial trend | FY2025 net sales rose 11.2% to $25.116 billion and reported net earnings rose to $3.246 billion. Q1 2026 sales rose 2.6% to about $6.0 billion despite operational disruption. | High |
| Valuation | At $329.74, financial_rigor.py calculates about 38.16x TTM EPS, 5.64x book value, 29.52x FCF, 5.00x sales, and a 1.02% dividend yield. | High |
| Technical trend | SYK is above Investing.com 50-day and 200-day moving averages near $323.77 and $311.09, while MarketWatch noted the stock remained 18.56% below its 52-week high. | Medium |
| Risk level | Risk is medium because procedure demand is healthy, but valuation, cyber disruption, supply execution, reimbursement, product liability, acquisitions, and hospital capital budgets matter. | Medium-high |
| AI confidence | High for historical financials and market data. Medium for forecast ranges because MedTech multiples and margins can re-rate quickly after execution misses. | High data confidence |
| Investment certainty | Medium certainty. Stryker is a strong business, but the current price offers less margin of safety if growth slows or adjusted EPS expectations are reset. | Medium |
SYK AI stock forecast
The SYK AI stock forecast is scenario-based around the $329.74 closing price. Using management-related 2026 adjusted EPS context near $15.00, financial_rigor.py produced three-year values near $635.90 in a bull case, $491.30 in a base case, and $286.50 in a bear case. These are not price promises. They show how sensitive SYK can be to EPS growth, margin recovery, and the earnings multiple investors assign to a premium MedTech compounder.
$600 to $640
More likely if organic sales return to high-single-digit or better growth, Q1 disruption is fully recovered, Mako and procedure volumes stay strong, margins expand, acquisitions integrate cleanly, and investors keep assigning SYK a premium low-30s earnings multiple.
$470 to $500
More likely if 2026 adjusted EPS lands near the guidance range, organic growth normalizes after the disrupted quarter, margins recover gradually, and SYK trades around a mid-20s earnings multiple on forward earnings.
$270 to $300
More likely if shipment disruption lingers, hospital capital budgets weaken, reimbursement or product liability risk rises, acquisitions dilute returns, or the market reprices SYK toward a lower MedTech multiple.
SYK AI technical analysis
SYK AI technical analysis is cautiously constructive as of the July 8, 2026 data cutoff. MarketWatch reported a July 7 close of $329.74 and 2.5 million shares traded, below a 50-day average volume near 2.8 million. Investing.com showed the 50-day moving average near $323.77 and the 200-day moving average near $311.09. The chart should be rechecked with live data before any trade.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $329.74 | July 7, 2026 closing quote used for this static page and market-cap verification. |
| Near support | $323 to $324 | The Investing.com 50-day moving average area is the first trend support after the rebound. |
| Deeper support | $311 to $315 | This band combines Investing.com 200-day moving-average context with the low end of analyst target ranges. |
| Near resistance | $334 to $350 | A break above this zone would clear nearby recovery resistance and the recent Evercore ISI target context. |
| Major resistance | $386 to $405 | StockAnalysis showed an average analyst target near $386.80, while MarketWatch cited a 52-week high near $404.87. |
| Moving averages | 50-day $323.77, 200-day $311.09 | Investing.com classified both moving-average signals as buy as of the data snapshot. |
| Momentum | Neutral to improving | The stock has recovered above common moving averages but remains far below the 52-week high, so momentum is not one-way. |
| Volume | 2.5 million vs 2.8 million 50-day average | MarketWatch reported July 7 volume below the 50-day average, so a breakout would need stronger sponsorship. |
| Volatility | Event-driven MedTech risk | Earnings, guidance updates, cyber recovery, procedure demand, product news, and acquisition integration can move the stock. |
| Invalidation | Close below $323, then $311 | A close below the 50-day average weakens the rebound. A close below the 200-day average would shift focus to downside risk control. |
SYK AI trading strategy
The SYK AI trading strategy is a rules-based framework, not a personalized recommendation. Use it with live charts, position sizing, earnings dates, hospital procedure data, FDA and product-liability news, cyber recovery updates, and clear invalidation levels.
Look for SYK to hold above the $323 to $324 moving-average area, then reclaim $334 to $350 on volume above the 50-day average and improving commentary around recovered shipments and 2026 adjusted EPS guidance.
A close below $323, or a failed breakout with rising down-day volume, should invalidate the near-term trend setup.
If SYK pulls back toward $311 to $315 without a new thesis break, compare the selloff with procedure demand, Mako adoption, organic sales recovery, operating margin, cash flow, and acquisition integration.
Do not treat franchise quality as a substitute for a stop or position limit because premium MedTech multiples can compress quickly.
Track organic sales growth, MedSurg and Neurotechnology momentum, Orthopaedics robotics adoption, adjusted operating margin, free cash flow, debt, acquisitions, cyber remediation, FDA updates, and product liability reserves.
Reduce confidence if revenue recovery is only timing catch-up, if margins fail to recover, or if guidance depends on multiple expansion rather than durable earnings growth.
Investment research summary
Stryker helps hospitals, surgeons, emergency teams, and healthcare systems improve patient outcomes with implants, instruments, surgical equipment, neurovascular tools, and procedure-enabling technology.
The moat is built from surgeon trust, training, switching costs inside operating-room workflows, Mako robotics, regulatory experience, distribution scale, broad product breadth, and long hospital relationships.
The thesis fails if procedure demand slows, the Q1 disruption reveals deeper operational risk, acquisitions dilute returns, product liability expands, reimbursement pressure rises, or the market stops paying for premium MedTech growth.
Kevin Lobo has compounded Stryker through innovation and acquisitions. The current test is whether management can protect growth, restore margins, integrate deals, and strengthen operational resilience after the cyber disruption.
Stryker sits inside durable healthcare trends: aging populations, orthopedic procedures, hospital productivity needs, surgical robotics, emergency care, neurovascular treatment, and global access to advanced medical devices.
The current price assumes high-quality growth and margin recovery. Margin of safety improves if SYK holds key technical support while guidance, procedure demand, free cash flow, and integration evidence remain intact.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| SYK price | $329.74 close on July 7, 2026 | StockAnalysis and MarketWatch quote snapshots | July 8, 2026 |
| Market capitalization | $126.41 billion, verified as $329.74 x 383.36 million shares | StockAnalysis statistics and financial_rigor.py verification | July 8, 2026 |
| Shares outstanding | 383.36 million shares outstanding | StockAnalysis statistics | July 8, 2026 |
| FY2025 revenue | $25.116 billion, cross-validated against Stryker 2025 Form 10-K, StockAnalysis, and Macrotrends | Stryker 2025 Form 10-K | July 8, 2026 |
| FY2025 net earnings | $3.246 billion, cross-validated against Stryker 2025 Form 10-K, Q4 release, and Macrotrends | Stryker 2025 Form 10-K | July 8, 2026 |
| FY2025 segment sales | MedSurg and Neurotechnology $15.6 billion; Orthopaedics $9.5 billion | Stryker Q4 2025 earnings release | July 8, 2026 |
| Q1 2026 sales | Reported net sales increased 2.6% to about $6.0 billion; reported operating income margin was 15.5% | Stryker Q1 2026 earnings release | July 8, 2026 |
| Cash and investments | $4.1 billion at FY2025, cross-validated against Stryker 2025 Form 10-K and Macrotrends cash-on-hand data | Stryker 2025 Form 10-K | July 8, 2026 |
| Long-term debt | $14.859 billion at FY2025; less $4.100 billion of cash and investments implies about $10.759 billion of net debt by financial_rigor.py calc | Macrotrends long-term debt data | July 8, 2026 |
| Free cash flow | $4.283 billion for FY2025 | Macrotrends free cash flow data | July 8, 2026 |
| Analyst price target context | StockAnalysis showed a consensus buy rating, $386.80 average target, $315 low target, and $465 high target | StockAnalysis forecast page | July 8, 2026 |
| 2026 guidance and disruption context | Full-year adjusted EPS guidance context was about $14.90 to $15.10, while Q1 revenue and EPS were affected by operational disruption | Stryker Q1 2026 earnings release and transcript coverage | July 8, 2026 |
| Technical moving averages | 50-day moving average $323.77; 200-day moving average $311.09 | Investing.com technical snapshot | July 8, 2026 |
| Management ownership context | StockAnalysis listed insider ownership at 9.24% and institutional ownership at 80.67% | StockAnalysis statistics | July 8, 2026 |
This SYK AI stock analysis is an informational research tool only. It is not investment advice, a recommendation, or a promise of future performance. Forecast ranges are scenarios based on available data as of July 8, 2026 and can be wrong if earnings, rates, procedure demand, regulation, litigation, acquisitions, cyber recovery, or market multiples change.
